http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 28 May 2026 17:21:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SOLIGENIX%2C+INC.+++++++++++For%3A+May+28/26568921.html si-local-file:///var/storage/secattach/20260528/26568921.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SOLIGENIX%2C+INC.+++++++++++For%3A+May+28/26568921.html Thu, 28 May 2026 17:21:00 -0400 O.01584314 SNGX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SOLIGENIX%2C+INC.+++++++++++For%3A+May+28/26568921.html si-local-file:///var/storage/secattach/20260528/26568921.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SOLIGENIX%2C+INC.+++++++++++For%3A+May+28/26568921.html Thu, 28 May 2026 17:21:00 -0400 O.01584314 SNGX http://www.streetinsider.com/SEC+Filings/Form++424B5++++++SOLIGENIX%2C+INC.++++++++++++++++++++++/26568913.html si-local-file:///var/storage/secattach/20260528/26568913.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++SOLIGENIX%2C+INC.++++++++++++++++++++++/26568913.html Thu, 28 May 2026 17:20:00 -0400 O.01584314 SNGX http://www.streetinsider.com/SEC+Filings/Form++424B5++++++SOLIGENIX%2C+INC.++++++++++++++++++++++/26568913.html si-local-file:///var/storage/secattach/20260528/26568913.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++SOLIGENIX%2C+INC.++++++++++++++++++++++/26568913.html Thu, 28 May 2026 17:20:00 -0400 O.01584314 SNGX http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses<br />may provide rapid starting point for vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695242-1&amp;h=3664158382&amp;u=http%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the recent Congo outbreak of Bundibugyo virus, an <i>Orthoebolavirus</i>, will require new vaccine formulation efforts. <span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span>, in collaboration with <person>Axel Lehrer</person>, PhD, Professor at the <span>Department http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html Tue, 26 May 2026 07:30:00 -0400 A.01316444 A.13092795 A.13522767 A.14320728 A.17568957 A.29922014 A.60012002 O.00651740 O.01584314 O.03289173 O.03297629 O.04889877 O.20250741 O.42081221 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses<br />may provide rapid starting point for vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695242-1&amp;h=3664158382&amp;u=http%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the recent Congo outbreak of Bundibugyo virus, an <i>Orthoebolavirus</i>, will require new vaccine formulation efforts. <span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span>, in collaboration with <person>Axel Lehrer</person>, PhD, Professor at the <span>Department http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html Tue, 26 May 2026 07:30:00 -0400 A.01316444 A.13092795 A.13522767 A.14320728 A.17568957 A.29922014 A.60012002 O.00651740 O.01584314 O.03289173 O.03297629 O.04889877 O.20250741 O.42081221 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses<br />may provide rapid starting point for vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695242-1&amp;h=3664158382&amp;u=http%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the recent Congo outbreak of Bundibugyo virus, an <i>Orthoebolavirus</i>, will require new vaccine formulation efforts. <span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span>, in collaboration with <person>Axel Lehrer</person>, PhD, Professor at the <span>Department http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html Tue, 26 May 2026 07:30:00 -0400 A.01316444 A.13092795 A.13522767 A.14320728 A.17568957 A.29922014 A.60012002 O.00651740 O.01584314 O.03289173 O.03297629 O.04889877 O.20250741 O.42081221 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses<br />may provide rapid starting point for vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695242-1&amp;h=3664158382&amp;u=http%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the recent Congo outbreak of Bundibugyo virus, an <i>Orthoebolavirus</i>, will require new vaccine formulation efforts. <span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span>, in collaboration with <person>Axel Lehrer</person>, PhD, Professor at the <span>Department http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html Tue, 26 May 2026 07:30:00 -0400 A.01316444 A.13092795 A.13522767 A.14320728 A.17568957 A.29922014 A.60012002 O.00651740 O.01584314 O.03289173 O.03297629 O.04889877 O.20250741 O.42081221 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses<br />may provide rapid starting point for vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695242-1&amp;h=3664158382&amp;u=http%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the recent Congo outbreak of Bundibugyo virus, an <i>Orthoebolavirus</i>, will require new vaccine formulation efforts. <span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span>, in collaboration with <person>Axel Lehrer</person>, PhD, Professor at the <span>Department http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html Tue, 26 May 2026 07:30:00 -0400 A.01316444 A.13092795 A.13522767 A.14320728 A.17568957 A.29922014 A.60012002 O.00651740 O.01584314 O.03289173 O.03297629 O.04889877 O.20250741 O.42081221 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses<br />may provide rapid starting point for vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695242-1&amp;h=3664158382&amp;u=http%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the recent Congo outbreak of Bundibugyo virus, an <i>Orthoebolavirus</i>, will require new vaccine formulation efforts. <span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span>, in collaboration with <person>Axel Lehrer</person>, PhD, Professor at the <span>Department http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html Tue, 26 May 2026 07:30:00 -0400 A.01316444 A.13092795 A.13522767 A.14320728 A.17568957 A.29922014 A.60012002 O.00651740 O.01584314 O.03289173 O.03297629 O.04889877 O.20250741 O.42081221 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses<br />may provide rapid starting point for vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695242-1&amp;h=3664158382&amp;u=http%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the recent Congo outbreak of Bundibugyo virus, an <i>Orthoebolavirus</i>, will require new vaccine formulation efforts. <span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span>, in collaboration with <person>Axel Lehrer</person>, PhD, Professor at the <span>Department http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html Tue, 26 May 2026 07:30:00 -0400 A.01316444 A.13092795 A.13522767 A.14320728 A.17568957 A.29922014 A.60012002 O.00651740 O.01584314 O.03289173 O.03297629 O.04889877 O.20250741 O.42081221 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses<br />may provide rapid starting point for vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695242-1&amp;h=3664158382&amp;u=http%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the recent Congo outbreak of Bundibugyo virus, an <i>Orthoebolavirus</i>, will require new vaccine formulation efforts. <span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span>, in collaboration with <person>Axel Lehrer</person>, PhD, Professor at the <span>Department http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html Tue, 26 May 2026 07:30:00 -0400 A.01316444 A.13092795 A.13522767 A.14320728 A.17568957 A.29922014 A.60012002 O.00651740 O.01584314 O.03289173 O.03297629 O.04889877 O.20250741 O.42081221 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses<br />may provide rapid starting point for vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695242-1&amp;h=3664158382&amp;u=http%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the recent Congo outbreak of Bundibugyo virus, an <i>Orthoebolavirus</i>, will require new vaccine formulation efforts. <span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span>, in collaboration with <person>Axel Lehrer</person>, PhD, Professor at the <span>Department http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html Tue, 26 May 2026 07:30:00 -0400 A.01316444 A.13092795 A.13522767 A.14320728 A.17568957 A.29922014 A.60012002 O.00651740 O.01584314 O.03289173 O.03297629 O.04889877 O.20250741 O.42081221 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses<br />may provide rapid starting point for vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695242-1&amp;h=3664158382&amp;u=http%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the recent Congo outbreak of Bundibugyo virus, an <i>Orthoebolavirus</i>, will require new vaccine formulation efforts. <span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span>, in collaboration with <person>Axel Lehrer</person>, PhD, Professor at the <span>Department http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html Tue, 26 May 2026 07:30:00 -0400 A.01316444 A.13092795 A.13522767 A.14320728 A.17568957 A.29922014 A.60012002 O.00651740 O.01584314 O.03289173 O.03297629 O.04889877 O.20250741 O.42081221 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses<br />may provide rapid starting point for vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695242-1&amp;h=3664158382&amp;u=http%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the recent Congo outbreak of Bundibugyo virus, an <i>Orthoebolavirus</i>, will require new vaccine formulation efforts. <span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span>, in collaboration with <person>Axel Lehrer</person>, PhD, Professor at the <span>Department http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html Tue, 26 May 2026 07:30:00 -0400 A.01316444 A.13092795 A.13522767 A.14320728 A.17568957 A.29922014 A.60012002 O.00651740 O.01584314 O.03289173 O.03297629 O.04889877 O.20250741 O.42081221 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses<br />may provide rapid starting point for vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695242-1&amp;h=3664158382&amp;u=http%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the recent Congo outbreak of Bundibugyo virus, an <i>Orthoebolavirus</i>, will require new vaccine formulation efforts. <span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span>, in collaboration with <person>Axel Lehrer</person>, PhD, Professor at the <span>Department http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html Tue, 26 May 2026 07:30:00 -0400 A.01316444 A.13092795 A.13522767 A.14320728 A.17568957 A.29922014 A.60012002 O.00651740 O.01584314 O.03289173 O.03297629 O.04889877 O.20250741 O.42081221 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses<br />may provide rapid starting point for vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695242-1&amp;h=3664158382&amp;u=http%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the recent Congo outbreak of Bundibugyo virus, an <i>Orthoebolavirus</i>, will require new vaccine formulation efforts. <span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span>, in collaboration with <person>Axel Lehrer</person>, PhD, Professor at the <span>Department http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html Tue, 26 May 2026 07:30:00 -0400 A.01316444 A.13092795 A.13522767 A.14320728 A.17568957 A.29922014 A.60012002 O.00651740 O.01584314 O.03289173 O.03297629 O.04889877 O.20250741 O.42081221 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses<br />may provide rapid starting point for vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695242-1&amp;h=3664158382&amp;u=http%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the recent Congo outbreak of Bundibugyo virus, an <i>Orthoebolavirus</i>, will require new vaccine formulation efforts. <span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span>, in collaboration with <person>Axel Lehrer</person>, PhD, Professor at the <span>Department http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html Tue, 26 May 2026 07:30:00 -0400 A.01316444 A.13092795 A.13522767 A.14320728 A.17568957 A.29922014 A.60012002 O.00651740 O.01584314 O.03289173 O.03297629 O.04889877 O.20250741 O.42081221 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses<br />may provide rapid starting point for vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695242-1&amp;h=3664158382&amp;u=http%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the recent Congo outbreak of Bundibugyo virus, an <i>Orthoebolavirus</i>, will require new vaccine formulation efforts. <span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span>, in collaboration with <person>Axel Lehrer</person>, PhD, Professor at the <span>Department http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html Tue, 26 May 2026 07:30:00 -0400 A.01316444 A.13092795 A.13522767 A.14320728 A.17568957 A.29922014 A.60012002 O.00651740 O.01584314 O.03289173 O.03297629 O.04889877 O.20250741 O.42081221 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses<br />may provide rapid starting point for vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695242-1&amp;h=3664158382&amp;u=http%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the recent Congo outbreak of Bundibugyo virus, an <i>Orthoebolavirus</i>, will require new vaccine formulation efforts. <span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span>, in collaboration with <person>Axel Lehrer</person>, PhD, Professor at the <span>Department http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html Tue, 26 May 2026 07:30:00 -0400 A.01316444 A.13092795 A.13522767 A.14320728 A.17568957 A.29922014 A.60012002 O.00651740 O.01584314 O.03289173 O.03297629 O.04889877 O.20250741 O.42081221 O.69857460 SNGX http://www.streetinsider.com/PRNewswire/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses<br />may provide rapid starting point for vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695242-1&amp;h=3664158382&amp;u=http%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the recent Congo outbreak of Bundibugyo virus, an <i>Orthoebolavirus</i>, will require new vaccine formulation efforts. <span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span>, in collaboration with <person>Axel Lehrer</person>, PhD, Professor at the <span>Department http://www.streetinsider.com/PRNewswire/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html Tue, 26 May 2026 07:30:00 -0400 A.01316444 A.13092795 A.13522767 A.14320728 A.17568957 A.29922014 A.60012002 O.00651740 O.01584314 O.03289173 O.03297629 O.04889877 O.20250741 O.42081221 O.69857460 SNGX http://www.streetinsider.com/PRNewswire/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses<br />may provide rapid starting point for vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695242-1&amp;h=3664158382&amp;u=http%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the recent Congo outbreak of Bundibugyo virus, an <i>Orthoebolavirus</i>, will require new vaccine formulation efforts. <span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span>, in collaboration with <person>Axel Lehrer</person>, PhD, Professor at the <span>Department http://www.streetinsider.com/PRNewswire/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html Tue, 26 May 2026 07:30:00 -0400 A.01316444 A.13092795 A.13522767 A.14320728 A.17568957 A.29922014 A.60012002 O.00651740 O.01584314 O.03289173 O.03297629 O.04889877 O.20250741 O.42081221 O.69857460 SNGX http://www.streetinsider.com/PRNewswire/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses<br />may provide rapid starting point for vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695242-1&amp;h=3664158382&amp;u=http%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the recent Congo outbreak of Bundibugyo virus, an <i>Orthoebolavirus</i>, will require new vaccine formulation efforts. <span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span>, in collaboration with <person>Axel Lehrer</person>, PhD, Professor at the <span>Department http://www.streetinsider.com/PRNewswire/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html Tue, 26 May 2026 07:30:00 -0400 A.01316444 A.13092795 A.13522767 A.14320728 A.17568957 A.29922014 A.60012002 O.00651740 O.01584314 O.03289173 O.03297629 O.04889877 O.20250741 O.42081221 O.69857460 SNGX http://www.streetinsider.com/PRNewswire/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses<br />may provide rapid starting point for vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695242-1&amp;h=3664158382&amp;u=http%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the recent Congo outbreak of Bundibugyo virus, an <i>Orthoebolavirus</i>, will require new vaccine formulation efforts. <span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span>, in collaboration with <person>Axel Lehrer</person>, PhD, Professor at the <span>Department http://www.streetinsider.com/PRNewswire/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html Tue, 26 May 2026 07:30:00 -0400 A.01316444 A.13092795 A.13522767 A.14320728 A.17568957 A.29922014 A.60012002 O.00651740 O.01584314 O.03289173 O.03297629 O.04889877 O.20250741 O.42081221 O.69857460 SNGX http://www.streetinsider.com/PRNewswire/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses<br />may provide rapid starting point for vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695242-1&amp;h=3664158382&amp;u=http%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the recent Congo outbreak of Bundibugyo virus, an <i>Orthoebolavirus</i>, will require new vaccine formulation efforts. <span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span>, in collaboration with <person>Axel Lehrer</person>, PhD, Professor at the <span>Department http://www.streetinsider.com/PRNewswire/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html Tue, 26 May 2026 07:30:00 -0400 A.01316444 A.13092795 A.13522767 A.14320728 A.17568957 A.29922014 A.60012002 O.00651740 O.01584314 O.03289173 O.03297629 O.04889877 O.20250741 O.42081221 O.69857460 SNGX